[1] Pang Q, Wei Q, Xu T, et al. Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys,2013,85(5):1332-1339. [2] Dunlap NE, Yang W, McIntosh A, et al. Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys,2012,84(5):1071-1077. [3] Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw,2017,15(4):504-535. [4] 杨龙海,叶波,魏星,等.最新国际肺癌TNM分期标准(第8版)修订稿解读[J].中国医刊,2016,51(9):22-25. [5] WHO handbook for reporting results of cancer treatment[M].Offset Publication No.48.Geneva(Switzedand):World Health Organization,1979. [6] 龚乐明.化疗及放化疗联合治疗局部晚期非小细胞肺癌的临床研究[J].医学临床研究,2011,28(1):92-93,96. [7] Wang Z, Zhu XX, Wu XH, et al. Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer[J]. Am J Clin Oncol,2014,37(2):148-153.
2019, Vol. 36 
